https://journaljcti.com/index.php/JCTI/issue/feed Journal of Cancer and Tumor International 2021-02-26T05:02:49+00:00 Journal of Cancer and Tumor International contact@journaljcti.com Open Journal Systems <p style="text-align: justify;"><strong>Journal of Cancer and Tumor International (ISSN: 2454-7360)</strong>&nbsp;aims to publish high quality papers (<a href="/index.php/JCTI/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of&nbsp;‘Cancer and&nbsp;Tumor research’. This journal facilitates the research and wishes to publish papers as long as they are technically correct, scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled,&nbsp;OPEN&nbsp;peer reviewed, open access INTERNATIONAL journal.</p> https://journaljcti.com/index.php/JCTI/article/view/30141 Postmenopausal Bleeding with an Accidental Discovery of an Ovarian Strumal Carcinoid Tumor: A Case Report 2021-02-25T10:31:59+00:00 Eman M. Ibrahim Salma S. El Ashwah Fatma I. El-Saeed Hosam A. F. Halim Amal A. F. Halim halim43210@mans.edu.eg <p><strong>Aim: </strong>Ovarian strumal carcinoid is a tumor formed of thyroid tissue and carcinoid elements. It represents less than 2% of all ovarian tumors and less than 5% of mature teratomas. Physicians in many lacations may not be aware about this pathology.</p> <p><strong>Presentation of Case: </strong>A multiparous 78-year-old woman presented&nbsp;&nbsp;&nbsp; by postmenopausal vaginal bleeding. The abdomen&amp; pelvic sonar detected&nbsp;&nbsp; atrophied endometrium and a right adnexal mass&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with mixed echogenicity and increased blood flow, a finding that was confirmed later with a pelvic MRI which revealed a well-defined mass of abnormal signal at the right adnexa showing cystic changes contacting anteriorly the related intestinal loops and the urinary bladder, while contacting posteriorly the recto-sigmoid.&nbsp; It measured8x6x6cm. Biopsy revealed atypical epithelial proliferation.&nbsp; CA125 was 90KU/L (normal range,0-35KU/L) while the levels of CEA, CA19-9 and alpha feto protein were normal. After discussion with the family, exploratory hysterectomy and bilateral salpingioophorectomy, along with omentectomy, peritoneal washing and peritoneal sampling were performed. Grossly, the right ovary was&nbsp;&nbsp;&nbsp; largely occupied by an ovoid mass (9cmx6cmx2 cm). The tumor was staged as IA according to AJCC 2010. Histological examination of the adnexal mass revealed admixture of benign thyroid tissue and tumor tissue formed of trabeculae &amp; nests of monotonous round cells. Such cells showed positivity for thyroglobulin, synaptophysin, chromogranin and low positivity for ki67 and so a diagnosis of&nbsp;&nbsp; strumal carcinoid tumor was documented. The patient was set to a close follow up. The last follow up was at August 2020 and was satisfactory.</p> <p><strong>Discussion and conclusion: </strong>Strumal carcinoids are rare. Pelvic sonar and CA125 are not specific diagnostic tools. They should be considered in the differential diagnosis of any ovarian mass. The disease usually presents at an&nbsp;&nbsp; early stage.</p> 2021-02-25T00:00:00+00:00 ##submission.copyrightStatement## https://journaljcti.com/index.php/JCTI/article/view/30140 Neoadjuvant Chemotherapy and Concomitant Boost Radiotherapy in the Treatment of Locally Advanced Rectal Cancer 2021-02-26T05:02:49+00:00 Mai AbdAllah Abdelazez Mai1Badawi1@gmail.com Soumaya Mohamed Eteba Eman Hamza Elzahhaf Sameh Roshdy Abdel Aziz Rehab Omar Eman Awad Abdallah <p><strong>Aims: </strong>This study aimed to examine the efficacy and toxicities of concomitant boost three-dimensional conformal radiotherapy along with multidrug chemotherapy (capecitabine and oxaliplatin) in neoadjuvant course for locally advanced rectal cancer (LARC).</p> <p><strong>Study Design:</strong> A phase II interventional nonrandomized study.</p> <p><strong>Place and Duration of Study: </strong>This Study was conducted at Clinical Oncology and nuclear medicine department of Mansoura University Hospitals (Egypt) between November 2016 and October 2019.</p> <p><strong>Methodology:</strong> Thirty patients (18 women, 12 men; age range 18-75 years) with (cT3-T4 and/or cN+) histologically confirmed rectal adenocarcinoma located within 12 cm of the anal verge were included in this study. Patients received three-dimensional conformal radiotherapy (3DCRT) to the pelvis of 45 Gy and a concomitant boost of 10 Gy to the primary tumor in 25 fractions, and concurrent with oxaliplatin (50 mg/m2 d1 weekly) and capecitabine (625 mg/m2 bid d1–5 weekly). Radical surgery was scheduled six to eight weeks after chemoradiation. Acute toxicities were recorded according to Common Terminology Criteria for Adverse Event (CTCAE) v5.0. Potential prognostic factors were evaluated using a binomial logistic regression. Survival curves were estimated using the Kaplan-Meier method and compared with Log-rank test.</p> <p><strong>Results:</strong> All patients received chemoradiation. Twenty-seven patients underwent surgical resection. Twenty-five patients underwent sphincter-sparing surgery (92.6%) and nine patients (33.3%) achieved pathological complete response (pCR). The incidences of grade III neutropenia, diarrhea, and radiation dermatitis were 6.7%, 6.7%, 3.3% respectively. The three-year local recurrence (LR), disease-free survival (DFS) and overall survival (OS) rates were 7.4%, 63% and 74.1%, respectively. We found pre-surgical negative nodal status to be significantly associated with pCR (p=0.009). The pathological nodal stage was an independent prognostic factor to DFS.</p> <p><strong>Conclusion: </strong>The combination of oxaliplatin, capecitabine, and dose escalation using concomitant boost 3DCRT is safely administrated in patients with locally advanced rectal adenocarcinoma and it offers high pCR and sphincter preservation rate.</p> 2021-02-23T00:00:00+00:00 ##submission.copyrightStatement##